Dolutegravir, Lamivudine, Tenofovir disoproxil fumarate

Dolutegravir, Lamivudine, and Tenofovir Disoproxil Fumarate (TDF) are three powerful antiretroviral drugs commonly used together in the treatment of HIV infection. This combination medication is designed to reduce the amount of HIV in the body and increase the number of immune cells, thus improving the quality of life for those living with the virus.
Dolutegravir, belonging to the integrase inhibitor class, works by stopping the HIV virus from integrating its genetic material into the DNA of human cells, thus preventing the virus from multiplying. Lamivudine, an nucleoside reverse transcriptase inhibitor (NUC), and Tenofovir Disoproxil Fumarate (TDF), a nucleotide reverse transcriptase inhibitor (NtRTI), both interfere with the virus’s ability to reproduce by blocking the action of key enzymes in the viral life cycle.
This combination medication is recommended for individuals with HIV who have not yet experienced treatment failure and have not developed resistance to any of the three drugs. By combining these medications, healthcare providers aim to achieve a more potent antiviral effect with fewer side effects and a simpler dosing regimen.
However, follow the prescribed dosing schedule and to inform healthcare professionals of any side effects or potential drug interactions. While this medication is an effective tool in the fight against HIV, it is not a cure for the disease, and patients must continue taking it as prescribed to maintain its therapeutic benefits.